Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.905 +0.125 (+2.16%)
Streaming Delayed Price Updated: 9:52 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,176
Open 5.960
Bid (Size) 5.890 (7)
Ask (Size) 5.920 (3)
Prev. Close 5.780
Today's Range 5.800 - 6.000
52wk Range 4.155 - 14.45
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
From Vir Biotechnology, Inc.
Via Business Wire

Performance

YTD
-18.8%
-18.8%
1 Month
+14.0%
+14.0%
3 Month
+7.0%
+7.0%
6 Month
+5.3%
+5.3%
1 Year
-22.8%
-22.8%

More News

Read More
Earnings Scheduled For August 6, 2025
Via Benzinga
This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Via Benzinga
This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Via Benzinga
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Via Benzinga
This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Vir (VIR) Q2 Revenue Drops 61%
Via The Motley Fool
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025
From Vir Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Where Vir Biotechnology Stands With Analysts
Via Benzinga
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
Via Benzinga
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?
Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
What is the current price of Vir Biotechnology, Inc. - Common Stock?
The current price of Vir Biotechnology, Inc. - Common Stock is 5.905
When was Vir Biotechnology, Inc. - Common Stock last traded?
The last trade of Vir Biotechnology, Inc. - Common Stock was at 10/20/25 09:52 AM ET
What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
The market capitalization of Vir Biotechnology, Inc. - Common Stock is 791.13M
How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
Vir Biotechnology, Inc. - Common Stock has 791M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.